[{"from": "human", "value": "Describe this molecule. [C][C][O][C][=C][Branch2][Ring2][S][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C@@H1][Branch1][#Branch2][C][S][=Branch1][C][=O][=Branch1][C][=O][C][N][C][=Branch1][C][=O][C][=C][Branch1][Branch1][C][Ring1][=Branch1][=O][C][=Branch1][=Branch1][=C][C][=C][Ring1][Branch2][N][C][=Branch1][C][=O][C][O][C]"}, {"from": "gpt", "value": "The molecule is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole]. Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation."}]